Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors
Information source: University of Colorado at Denver and Health Sciences Center
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Advanced Solid Tumors
Intervention: Vorinostat and sorafenib (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: University of Colorado at Denver and Health Sciences Center
Summary
The main purpose of this study is to:
- Evaluate the safety of vorinostat in combination with sorafenib.
- Determine the largest dose of vorinostat + sorafenib that can be given safely to
humans.
- Determine if vorinostat + sorafenib are effective in stopping tumors from growing or in
decreasing their size.
- Study the side effects of vorinostat + sorafenib.
Clinical Details
Official title: A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase 2 Dose (Renal Cell Carcinoma and Non-Small Cell Lung Carcinoma)
Study design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Eligibility criteria include but are not limited to:
- 18 years or older with advanced solid tumor(s),
- Renal cell or non-small cell lung cancer.
Locations and Contacts
University of Colorado Cancer Center, Aurora, Colorado 80045, United States; Recruiting
Stacy Grolnic, Phone: 720-848-0655, Email: stacy.grolnic@uchsc.edu
Additional Information
Starting date: March 2008
Last updated: March 13, 2008
|
